Fennec Pharmaceuticals Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), the first and only FDA-approved therapy to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also holds an exclusive license with Norgine Pharma to commercialize the product (branded as PEDMARQSI®) in Europe, Australia, and New Zealand.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $12.46 million | $6.97 million | $30.87 million | $39.61 million |
| Net Loss | $(0.64) million | $(5.74) million | $(4.95) million | $1.55 million (Income) |
| Operating Loss | $(0.19) million | $(5.20) million | $(3.73) million | $3.50 million (Income) |
| Cash and Equivalents | $21.95 million (as of Sept 30, 2025) | |||
| Working Capital | $36.25 million (as of Sept 30, 2025) | |||
| Long-Term Debt (Net) | $19.38 million (as of Sept 30, 2025) | |||
| Stockholders' Deficit | $(4.49) million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 product sales increased 79% to $12.46 million compared to $6.97 million in Q3 2024, driven by expanded market penetration and focus on the Adolescent and Young Adult (AYA) population. YTD revenue decreased primarily due to the absence of $17.96 million in one-time licensing revenue recognized in Q1 2024 from the Norgine agreement.
- Profitability Improvement: The company significantly reduced its net loss in Q3 2025 to $0.64 million from $5.74 million in the prior year quarter. Operating expenses decreased slightly in Q3, while interest expense dropped by $0.44 million due to a $13.0 million debt paydown in December 2024.
- Cash Flow: Net cash used in operating activities was $6.51 million for the nine months ended Sept 30, 2025, compared to $28.45 million provided in the same period in 2024. The prior year's positive cash flow was heavily influenced by the $43.2 million upfront payment from the Norgine licensing deal.
- Debt Reduction: Following the redemption of $13.0 million in notes in late 2024, outstanding long-term debt (including PIK interest) stands at approximately $19.48 million.
Outlook, Risks, and Contingencies
- Liquidity: Management believes current funds, bolstered by the Norgine upfront payment, are sufficient to fund operations for at least the next 12 months.
- Patent Litigation: Ongoing litigation against CIPLA Ltd. regarding generic versions of PEDMARK. The company has secured Orphan Drug Exclusivity until September 2029, preventing FDA approval of a generic ANDA until that date. Recent court rulings in July 2025 adopted the company's claim constructions.
- Regulatory & Tax: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 on its tax provisions. Tariffs are currently not expected to have a material impact.
- Stock-Based Compensation: Significant non-cash expense of $4.51 million was recorded for the nine months ended Sept 30, 2025, related to employee stock options and performance-based units (PSUs).
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of PEDMARK product sales growth in the absence of the large one-time licensing revenue recognized in 2024.
- Cash Burn Rate: Monitor the negative operating cash flow ($6.51M YTD) against the current cash balance ($21.95M) to assess runway without further capital raises.
- Debt Obligations: Review the terms of the remaining $19.48 million in convertible notes, including the interest rate (Prime + 4.5%) and maturity date (August 2027).
- Patent Defense: Track the status of the CIPLA litigation and the effectiveness of the Orphan Drug Exclusivity protection through 2029.
- European Commercialization: Assess the progress of Norgine's commercialization of PEDMARQSI in Europe, Australia, and New Zealand, including royalty recognition potential.